MedImmune, Inc. v. Genentech, Inc.
Headline: Patent licensees allowed to challenge patents without breaking licenses, letting companies seek court rulings on patent validity while continuing to pay royalties and avoid immediate business risks.
Holding: The Court held that a patent licensee may seek a federal declaratory judgment about the patent’s validity, enforceability, or infringement without first terminating or breaching its license agreement.
- Allows licensees to challenge patent validity while still paying royalties.
- Prevents firms from having to stop payments and risk treble damages before suing.
- Leaves lower courts to decide equitable defenses and merits on remand.
Summary
Background
MedImmune, a drug maker that sells Synagis, had a license with Genentech covering a patent called Cabilly II. Genentech told MedImmune that Synagis was covered by the patent and demanded royalties beginning in 2002. MedImmune paid the royalties under protest because it believed the patent was invalid, unenforceable, and not infringed, but feared treble damages, attorney’s fees, and an injunction that could stop sales and destroy most of its revenue. It then sued for a declaration that it owed no royalties.
Reasoning
The Court considered whether a licensee must break or be in breach of its license before asking a federal court to decide patent validity or noninfringement. Relying on past decisions, the Court said Article III allows a declaratory judgment when there is a substantial, immediate dispute, even if the licensee continues paying royalties under coercive circumstances. It rejected the Federal Circuit rule that payment in good standing wipes out jurisdiction, and it reversed the dismissal, leaving merits and discretionary issues for lower courts.
Real world impact
The ruling lets companies challenge patent validity without first stopping payments and risking ruin. It protects businesses that pay royalties under protest from having to “bet the farm” before seeking a court ruling. The decision does not resolve whether courts should refuse relief on equitable grounds; lower courts will consider those questions on remand.
Dissents or concurrances
Justice Thomas dissented, arguing that MedImmune sought an advisory opinion about a future defense and that Article III forbids premature rulings when no present threat of suit exists.
Opinions in this case:
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?